Trial Profile
Dynamic-contrast enhanced MRI [magnetic resonance imaging] pharmacodynamic study of BAY 43-9006 [sorafenib] in metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Sep 2012
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 05 Mar 2008 New trial record.